Sidley Represents Jiangsu Nhwa Pharmaceutical in Its US$517.5 Million Licensing Transaction With Somnivera
September 30, 2026
September 30, 2026
CHICAGO, Illinois, Sept. 30 [Category: BizLaw/Legal] -- Sidley Austin, a law firm, posted the following news release:
* * *
Sidley Represents Jiangsu Nhwa Pharmaceutical in Its US$517.5 Million Licensing Transaction With Somnivera
*
Sidley represented Jiangsu Nhwa Pharmaceutical Co. in an agreement with newly formed biotechnology company Somnivera for the ex-China rights to a clinical-stage sleep disorder drug. Under the agreement, Jiangsu Nhwa . . .
* * *
Sidley Represents Jiangsu Nhwa Pharmaceutical in Its US$517.5 Million Licensing Transaction With Somnivera
*
Sidley represented Jiangsu Nhwa Pharmaceutical Co. in an agreement with newly formed biotechnology company Somnivera for the ex-China rights to a clinical-stage sleep disorder drug. Under the agreement, Jiangsu Nhwa . . .